{"id":506113,"date":"2025-02-12T06:50:23","date_gmt":"2025-02-12T03:50:23","guid":{"rendered":"https:\/\/analyse.optim.biz\/?p=506113"},"modified":"2025-02-12T06:50:23","modified_gmt":"2025-02-12T03:50:23","slug":"tratament-tintit-anti-cancer-dezvoltat-preclinic-de-cercetatorii-clujeni-ai-universitatii-de-medicina-poate-inlocui-chimioterapia","status":"publish","type":"post","link":"https:\/\/analyse.optim.biz\/?p=506113","title":{"rendered":"Tratament \u021bintit anti-cancer, dezvoltat preclinic de cercet\u0103torii clujeni ai Universit\u0103\u021bii de Medicin\u0103 \/ Poate \u00eenlocui chimioterapia"},"content":{"rendered":"<div class=\"post-content\">\n<p>O echip\u0103 de cercet\u0103tori a Universit\u0103\u021bii de Medicin\u0103 \u0219i Farmacie \u201dIuliu Ha\u021bieganu\u201d (UMFIH) Cluj-Napoca lucreaz\u0103 la un proiect de dezvoltare a unui tratament \u021bintit anti-cancer, care poate reduce dozele de chimioterapie \u0219i diminueaz\u0103, astfel, efectele adverse pentru pacien\u021bi, anun\u021b\u0103 <a href=\"https:\/\/cluj24.ro\/tratament-tintit-anti-cancer-dezvoltat-preclinic-de-cercetatorii-clujeni-ai-umfih-poate-inlocui-chimioterapia-236988.html\" target=\"_blank\" rel=\"noopener\"><strong>Cluj24.<\/strong><\/a><\/p>\n<p>Dr. Ciprian Tomuleasa, cercet\u0103tor din partea UMFIH, a explicat proiectul propune o nou\u0103 abordare terapeutic\u0103 pentru pacien\u021bii cu cancer, \u0219i anume imunoterapia.<\/p>\n<p>\u201d\u00cen departamentul nostru de la Centrul de Cercet\u0103ri pentru Medicin\u0103 Avansat\u0103 \u2013 Medfuture al UMFIH Cluj-Napoca avem un proiect mai complex, cu un director de proiect str\u0103in, care este pre\u0219edintele Societ\u0103\u021bii Germane de Hematologie \u0219i Oncologie, profesorul Hermann Einsele din W\u00fcrzburg, prorector \u0219tiin\u021bific al Universit\u0103\u021bii din W\u00fcrzburg \u0219i unul dintre top 10 hematologi la nivel mondial, \u00een special pe domeniul mielomului multiplu \u0219i al transplantului.<\/p>\n<p>Practic, \u00eempreun\u0103 cu echipa sa, dorim s\u0103 propunem o nou\u0103 abordare terapeutic\u0103 pentru pacien\u021bii cu cancer. Este vorba despre\u00a0 imunoterapie, care se bazeaz\u0103 pe limfocitele T modificate genetic, pe care le vom testa at\u00e2t in vitro, pe culturi celulare \u0219i pe modele animale ale afec\u021biunilor, iar, ulterior, vom publica datele\u201d, a spus dr. Tomuleasa.<\/p>\n<p>Potrivit acestuia, publicarea rezultatelor cercet\u0103rii va fi urmat\u0103 de trialuri pe pacien\u021bi \u0219i ulterior, probabil \u00een 10 ani, cercetarea ar putea fi aplicat\u0103 \u00een practica medical\u0103 curent\u0103.<\/p>\n<p>Pentru pacien\u021bii bolnavi de cancer, abordarea pe imunoterapie este una de tip \u201dchemotherapy free\u201d, ceea ce \u00eenseamn\u0103 c\u0103 nu ar mai fi nevoie, cel pu\u021bin teoretic, de chimioterapie.<\/p>\n<div class=\"code-block code-block-15\">\n<h4>Urm\u0103re\u0219te mai jos produc\u021biile video ale G4Media:<\/h4>\n<\/div>\n<\/div>\n<p> Source URL: https:\/\/www.g4media.ro\/tratament-tintit-anti-cancer-dezvoltat-preclinic-de-cercetatorii-clujeni-ai-universitatii-de-medicina-poate-inlocui-chimioterapia.html<\/p>\n","protected":false},"excerpt":{"rendered":"<p>O echip\u0103 de cercet\u0103tori a Universit\u0103\u021bii de Medicin\u0103 \u0219i Farmacie \u201dIuliu Ha\u021bieganu\u201d (UMFIH) Cluj-Napoca lucreaz\u0103 la un proiect de dezvoltare a unui tratament \u021bintit anti-cancer, care poate reduce dozele de chimioterapie \u0219i diminueaz\u0103, astfel, efectele adverse pentru pacien\u021bi, anun\u021b\u0103 Cluj24. Dr. Ciprian Tomuleasa, cercet\u0103tor din partea UMFIH, a explicat proiectul propune o nou\u0103 abordare terapeutic\u0103 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":506114,"comment_status":"open","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[2],"tags":[24],"class_list":["post-506113","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-politics","tag-g4media"],"_links":{"self":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/506113","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=506113"}],"version-history":[{"count":0,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/posts\/506113\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=\/wp\/v2\/media\/506114"}],"wp:attachment":[{"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=506113"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=506113"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/analyse.optim.biz\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=506113"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}